Undefeated Light Heavyweight Hisaki Kotoku knocks out Richard Nurse in six seconds at A1 Combat Prospect Series in Sacramento ...

Here are all the highlights of Winterthur's biggest offering of the year, one of Delaware's most anticipated seasonal events. Point-to-Point at Winterthur is best known for its heart-pounding ...

Combo Attack II is one of the many Pictos you can acquire in Clair Obscur: Expedition 33, but where can you find it and what does it do? This page acts as a comprehensive breakdown of the Combo ...

The defending Stanley Cup champion Florida Panthers are one win away from a third consecutive trip to the conference final and from extending the Toronto Maple Leafs' playoff misery. The Panthers ...

Linus Ullmark made 27 saves for his first career playoff shutout in the Ottawa Senators' 4-0 win over the host Toronto Maple Leafs on Tuesday night in Game 5 of their Eastern Conference best-of ...

Alabama baseball got a brief break after its sweep of Missouri, but the Crimson Tide couldn't continue its streak in Nashville. At No. 15 Vanderbilt, No. 16 Alabama (36-12, 13-11 SEC) bounced back ...

Michigan tight end Colston Loveland was drafted 10th overall by the Chicago Bears, making him the highest-drafted tight end in Michigan history. Loveland finished his Michigan career with 117 ...

Not only has Manon helped popularize the straight eyebrow trend on TikTok, but the group's very own leader, Sophia Laforteza, has had everyone searching high and low for her go-to lip combo for ...

Which two teams will reach the NBA Finals? We'll have complete coverage of the playoffs all the way until the champion is crowned. (The 2025 Finals tip off June 5 on ABC and the ESPN App.) Note ...

Tampa Bay Buccaneers Head Coach Todd Bowles spoke to the media after the first day of the Bucs' 2025 OTAs. HC Bowles discussed wanting to come down with more interceptions in 2025, OC Josh ...

Both teams were eliminated in the second round. This page will be your home throughout the postseason, including schedules, scores, highlights and other preview content. Read on for the full ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.